PCMP-A6 Antibody

What are the different types of A6-designated antibodies in research?

Several antibodies with the A6 designation appear in scientific literature, each with distinct targets and applications. The monoclonal antibody A6.4.12 targets Poly(ADP-Ribose) Polymerase-1 (PARP-1), a ~116 kDa nuclear enzyme involved in DNA damage repair . The monoclonal antibody A-6 recognizes human TERT (telomerase reverse transcriptase) . Another monoclonal antibody (A6) has specificity for lipid A, with preference for the bisphosphorylated (native) form . Additionally, there's a monoclonal antibody A6 that recognizes a unique epitope strongly expressed on the lower MW isoform (p180) of leukocyte common antigen (LCA) . Finally, the monoclonal antibody 24-A6 targets the M protein of Porcine Deltacoronavirus (PDCoV) . Each of these antibodies serves specific research purposes, requiring careful selection based on experimental objectives.

How do I determine the appropriate A6 antibody for my specific research application?

Selecting the appropriate A6 antibody depends on your target antigen and experimental goals. First, clearly identify your target molecule (PARP-1, TERT, lipid A, LCA, or viral proteins). Next, review literature for validated applications of specific A6 antibodies with your target. For instance, PARP-1 A6.4.12 antibody is validated for Western blotting (1/1000-1/5000 dilution) , while TERT Antibody A-6 is suitable for Western blotting, immunoprecipitation, immunofluorescence, immunohistochemistry with paraffin-embedded sections, and ELISA . Consider factors like species specificity, epitope recognition, and required applications (IHC, WB, IF, etc.). Finally, pilot experiments with positive and negative controls are essential to validate antibody performance in your specific experimental context.

What are the recommended storage conditions for A6 antibodies?

Most A6 antibodies should be stored according to manufacturer specifications, typically at -20°C for long-term storage. For instance, the PARP-1 antibody clone A6.4.12 preparation is stored in phosphate-buffered saline with 0.09% sodium azide as preservative . Avoid repeated freezing and thawing as this may denature the antibody, and storage in frost-free freezers is not recommended . For working stocks, small aliquots should be prepared to minimize freeze-thaw cycles. Some antibodies, like purified Fab fragments, may be stored at 4°C for short periods (as in the case of anti-lipid A antibodies) . Always check the specific storage requirements for your particular A6 antibody, as conditions may vary based on formulation, conjugation, and concentration.

How should I design an antibody panel incorporating A6 antibodies for flow cytometry?

When designing a flow cytometry panel including A6 antibodies, follow these methodological steps:

• Know your instrument limitations regarding available lasers and detectors .

• Prioritize "rare" antigens or those with lower expression by matching them with bright fluorophores .

• Match high-expressed antigens with less bright fluorophores .

• Consider the expression pattern of your target: For instance, when using A6 that recognizes LCA, note that it stains most TCR-alpha beta+ cells with differential intensities and strongly stains all TCR-gamma delta+ cells, but doesn't stain CD19+ B cells or CD56+ NK cells .

• Account for potential spectral overlap and include appropriate compensation controls.

• Include relevant functional markers based on your research question.

Example Panel Design for T Cell Memory Subsets Using A6 Antibody:

This design allows comprehensive identification of functional T cell subsets while leveraging the unique properties of the A6 antibody to distinguish memory populations.

What antigen retrieval methods are recommended for immunohistochemistry with A6 antibodies?

Antigen retrieval methods vary depending on the specific A6 antibody and target tissue. For PARP-1 antibody clone A6.4.12, heat treatment is required prior to staining paraffin sections, with sodium citrate buffer pH 6.0 specifically recommended for this purpose . This heat-induced epitope retrieval (HIER) method helps expose antigenic sites that may be masked during fixation and embedding processes.

For other A6 antibodies, the optimal retrieval method should be determined empirically, considering:

• Fixation method used (formalin, paraformaldehyde, etc.)

• Tissue type (brain, cardiac, etc.)

• Target antigen location (nuclear, cytoplasmic, membrane)

• Specific epitope characteristics (conformational vs. linear)

A systematic approach involves testing multiple retrieval methods:

• Citrate buffer (pH 6.0) with heat

• EDTA buffer (pH 8.0-9.0) with heat

• Enzymatic retrieval (proteinase K, trypsin)

• No retrieval (for some tissues/targets)

Follow with careful optimization of primary antibody concentration, incubation time, and temperature to achieve optimal signal-to-noise ratio.

How can I verify the specificity of A6 antibody binding in my experiments?

Verifying antibody specificity is crucial for reliable research outcomes. For A6 antibodies, implement these methodological approaches:

• Positive and negative controls: Include tissues or cell lines known to express or lack your target. For instance, PARP-1 A6.4.12 antibody should show nuclear staining in most cell types, while the A6 antibody against LCA should stain T cells but not B cells or NK cells .

• Knockout/knockdown validation: Compare staining between wild-type and knockout/knockdown samples. For example, research has shown detection of a truncated form of PARP-1 (lacking residues encoded by exon 2) in some PARP-1 knockout strains , which provides important context for interpreting results.

• Peptide competition: Pre-incubate the antibody with the immunizing peptide before staining. For example, the epitope recognized by mAb 24-A6 (103SPESRL108) could be synthesized and used for competition assays .

• Multiple antibodies to the same target: Compare staining patterns with antibodies recognizing different epitopes of the same protein.

• Cross-reactivity assessment: Test against similar proteins or species homologs. The conservation analysis of the 103SPESRL108 epitope in the PDCoV M protein shows 33.3% sequence similarity to other porcine coronaviruses but 83-100% similarity among deltacoronaviruses, suggesting potential cross-reactivity with other deltacoronaviruses .

• Immunoprecipitation followed by mass spectrometry: Identify all proteins captured by the antibody to confirm target specificity.

What are the common causes of inconsistent results when using A6 antibodies in Western blotting?

Inconsistent Western blot results with A6 antibodies may stem from several methodological issues:

• Sample preparation problems:

  • Inadequate protein extraction

  • Protein degradation (add protease inhibitors)

  • Incomplete denaturation or reduction

  • Inconsistent loading amounts

• Antibody-specific factors:

  • Using suboptimal dilutions (e.g., for PARP-1 A6.4.12, the recommended range is 1/1000-1/5000 )

  • Antibody degradation from improper storage

  • Batch-to-batch variations

  • Inadequate blocking or non-specific binding

• Target-specific considerations:

  • Post-translational modifications affecting epitope accessibility

  • PARP-1 cleavage during apoptosis, yielding multiple bands

  • For TERT, alternative splicing variants may affect detection

• Technical variables:

  • Inconsistent transfer efficiency

  • Variable blocking effectiveness

  • Exposure time differences

  • Secondary antibody variability

Methodological Solutions:

• Standardize protein extraction and quantification

• Optimize antibody concentration with titration experiments

• Include positive controls in every experiment

• For PARP-1 detection, note that during apoptosis, PARP-1 is cleaved, potentially yielding multiple bands

• Maintain consistent blotting conditions (transfer time, buffer composition, blocking agents)

• Consider using automated Western blotting systems for greater reproducibility

How can I distinguish between specific and non-specific binding in immunofluorescence studies with A6 antibodies?

Differentiating specific from non-specific binding in immunofluorescence using A6 antibodies requires systematic controls and careful analysis:

• Control experiments:

  • Isotype controls matching the primary antibody's isotype (e.g., IgG1 for PARP-1 A6.4.12 )

  • Secondary antibody only controls to assess background

  • Blocking peptide competition to confirm epitope specificity

  • Known positive and negative cell types or tissues

• Signal validation strategies:

  • Expected subcellular localization (e.g., nuclear for PARP-1, membrane-associated for the LCA-specific A6)

  • Colocalization with established markers

  • Comparison with other detection methods (Western blot, IHC)

  • Knockout/knockdown validation

• Technical optimization:

  • Optimize fixation methods (some epitopes are fixation-sensitive)

  • Test different permeabilization protocols

  • Vary blocking reagents (BSA, serum, commercial blockers)

  • Adjust antibody concentration and incubation conditions

  • Use higher affinity detection systems for weak signals

• Advanced approaches:

  • Super-resolution microscopy for precise localization

  • Spectral imaging to distinguish autofluorescence

  • FRET assays to confirm proximity to known interacting partners

  • Live-cell antibody visualization (for non-fixed applications)

How can A6 antibodies be used to investigate protein-protein interactions and complex formation?

A6 antibodies can be valuable tools for studying protein-protein interactions through several methodological approaches:

• Co-immunoprecipitation (Co-IP):

  • Use A6 antibodies to pull down the target protein and associated complexes

  • For example, TERT Antibody (A-6) can be used for immunoprecipitation to identify TERT-interacting proteins

  • The immunoprecipitation protocol can be adapted from methods used for other antibodies, such as dialyzing into buffer, purification by chromatography, and concentration to 10-12 mg/ml

• Proximity Ligation Assay (PLA):

  • Combine A6 antibody with antibodies against potential interacting partners

  • Generates fluorescent signals only when proteins are in close proximity

  • Particularly useful for validating interactions in situ

• Chromatin Immunoprecipitation (ChIP):

  • For nuclear proteins like PARP-1 (targeted by A6.4.12), ChIP can identify DNA binding sites

  • Can be combined with sequencing (ChIP-seq) for genome-wide interaction mapping

  • Particularly relevant given PARP-1's role in DNA damage repair

• Bimolecular Fluorescence Complementation (BiFC):

  • Fuse potential interacting proteins with complementary fragments of fluorescent proteins

  • Use A6 antibodies to confirm expression of fusion proteins

  • Visualize interactions through reconstituted fluorescence

• FRET/FLIM:

  • Combine A6 antibodies conjugated with donor fluorophores with acceptor-labeled antibodies against interacting partners

  • Measure energy transfer as indication of proximity

  • Particularly useful for dynamic interactions

• Mass Spectrometry-Based Approaches:

  • Use A6 antibodies for immunoprecipitation followed by mass spectrometry

  • Identify novel interaction partners in an unbiased manner

  • Quantify interaction dynamics under different experimental conditions

What are the considerations for epitope mapping of A6 antibodies?

Epitope mapping for A6 antibodies requires a systematic approach to identify the specific antigenic determinants recognized by these antibodies:

• Peptide Array Analysis:

  • Synthesize overlapping peptides spanning the target protein

  • Screen for antibody binding to identify reactive peptides

  • As demonstrated for mAb 24-A6, which identified 103SPESRL108 as the minimal linear epitope

  • This approach works best for linear epitopes

• Mutagenesis Approaches:

  • Generate point mutations or deletions in the target protein

  • Express mutant proteins and test for antibody binding

  • Loss of binding indicates critical residues within the epitope

  • This approach can work for both linear and conformational epitopes

• X-ray Crystallography/Cryo-EM:

  • Determine 3D structure of antibody-antigen complexes

  • Provides atomic-level details of interaction interfaces

  • As used for mAbs against lipid A, revealing different combining-site pockets complementary to the antigen

  • Most definitive but technically challenging

• Hydrogen-Deuterium Exchange Mass Spectrometry (HDX-MS):

  • Compare deuterium uptake of protein alone versus antibody-bound

  • Reduced exchange indicates protected regions (potential epitopes)

  • Useful for conformational epitopes

• Cross-reactivity Analysis:

  • Test antibody binding to homologous proteins from different species

  • Align sequences to identify conserved regions associated with binding

  • For example, the epitope recognized by mAb 24-A6 showed 83-100% similarity among deltacoronaviruses but only 33.3% similarity to other porcine coronaviruses

• Computational Prediction:

  • Use algorithms to predict antigenic regions based on protein properties

  • Combine with experimental validation for higher confidence

  • Particularly useful for initial hypothesis generation

How can I use A6 antibodies for investigating post-translational modifications of proteins?

A6 antibodies can be valuable tools for studying post-translational modifications (PTMs) through these methodological approaches:

• PTM-Specific Detection:

  • Determine if the A6 antibody epitope contains or is affected by PTM sites

  • For PARP-1 (recognized by A6.4.12), consider that the enzyme undergoes auto-PARylation

  • For TERT (recognized by A-6), phosphorylation states can affect telomerase activity

  • The carbohydrate-dependent epitope recognized by A6 on LCA was neuraminidase-sensitive but trypsin-resistant, indicating glycosylation involvement

• PTM-Dependent Binding Analysis:

  • Compare antibody binding before and after enzymatic removal of PTMs

  • For glycosylation-dependent epitopes (like the A6 epitope on LCA), treat samples with glycosidases

  • For phosphorylation, use phosphatase treatment

  • Changes in binding indicate PTM-dependent epitopes

• Co-localization Studies:

  • Combine A6 antibodies with PTM-specific antibodies

  • Assess co-localization in different cellular compartments or under various conditions

  • Particularly useful for dynamic PTM processes

• Sequential Immunoprecipitation:

  • First immunoprecipitate with PTM-specific antibodies

  • Then probe with A6 antibodies (or vice versa)

  • Quantify the fraction of the protein carrying specific modifications

• Stimulus-Response Analysis:

  • Monitor changes in A6 antibody binding following stimuli known to induce PTMs

  • For example, DNA damage induces PARP-1 activation and auto-modification

  • Time-course experiments can reveal PTM dynamics

• Proteomics Integration:

  • Use A6 antibodies for enrichment prior to mass spectrometry

  • Identify and quantify multiple PTM types on the target protein

  • Compare PTM patterns under different experimental conditions

How can A6 antibodies be utilized in single-cell analysis techniques?

A6 antibodies can enhance single-cell analysis through several methodological implementations:

• Single-Cell Flow Cytometry:

  • Incorporate A6 antibodies into multiparameter panels

  • For A6 antibody recognizing LCA, it can subdivide TCR-alpha beta+ cells into bright and dim populations

  • Enable high-dimensional phenotyping when combined with other markers

  • Use fluorescence-activated cell sorting (FACS) to isolate specific subpopulations for downstream analysis

• Mass Cytometry (CyTOF):

  • Conjugate A6 antibodies with rare metal isotopes

  • Integrate into 40+ parameter panels without fluorescence spillover concerns

  • Particularly valuable for deeply phenotyping heterogeneous cell populations

• Single-Cell RNA-Seq Integration:

  • Use A6 antibodies for cell sorting prior to scRNA-seq

  • Apply CITE-seq/REAP-seq methods to simultaneously detect surface proteins and transcriptomes

  • Correlate protein expression (by antibody binding) with gene expression patterns

• Imaging Mass Cytometry/Multiplexed Ion Beam Imaging:

  • Apply metal-conjugated A6 antibodies to tissue sections

  • Achieve subcellular resolution with 40+ markers

  • Preserve spatial context while obtaining single-cell data

• Microfluidic Approaches:

  • Integrate A6 antibodies into microfluidic antibody capture assays

  • Perform single-cell secretion profiling

  • Combine with imaging for temporal analysis of cellular responses

• Spatial Transcriptomics Correlation:

  • Use A6 antibodies for immunofluorescence on tissue sections

  • Correlate with spatial transcriptomics data from adjacent sections

  • Bridge protein localization with gene expression patterns at near-single-cell resolution

What are the considerations for using A6 antibodies in multiplexed immunofluorescence studies?

Implementing A6 antibodies in multiplexed immunofluorescence requires careful methodological planning:

• Panel Design Strategy:

  • Start with rare antigens or critical markers (potentially including A6-targeted antigens)

  • Match antibody brightness with target expression levels

  • Consider the spectral properties of the detection system

  • Account for potential cross-reactivity between antibodies

• Antibody Validation for Multiplexing:

  • Test each antibody individually before combining

  • Verify that antibody performance isn't compromised in multiplex settings

  • Confirm that staining patterns match expected biology

  • For A6 antibodies like the one recognizing LCA, verify expected staining patterns on T cells versus B and NK cells

• Technical Approaches:

  • Sequential Staining: Apply, image, and remove/quench antibodies sequentially

  • Spectral Unmixing: Use spectral detectors to separate overlapping fluorophores

  • Direct vs. Indirect Detection: Consider primary antibody labeling versus secondary detection

  • Tyramide Signal Amplification: Enhance sensitivity for low-abundance targets

• Controls for Multiplexed Systems:

  • Single-color controls for spectral compensation/unmixing

  • FMO (Fluorescence Minus One) controls to set boundaries

  • Isotype controls for each species/isotype used

  • Biological controls (positive/negative tissues or conditions)

• Image Analysis Considerations:

  • Automated cell segmentation algorithms

  • Colocalization quantification methods

  • Spatial relationship analysis between different markers

  • Machine learning approaches for pattern recognition

• Troubleshooting Multiplex-Specific Issues:

  • Antibody steric hindrance when targets are in close proximity

  • Order-dependent effects in sequential staining

  • Signal-to-noise challenges with increasing marker numbers

  • Photobleaching during extended imaging sessions

How can I optimize A6 antibodies for super-resolution microscopy applications?

Optimizing A6 antibodies for super-resolution microscopy requires specific methodological adaptations:

• Conjugation Strategies:

  • Direct conjugation with appropriate fluorophores (Alexa Fluor dyes, Atto dyes, Janelia Fluor dyes)

  • For TERT Antibody (A-6), consider using available Alexa Fluor conjugates

  • Select fluorophores with properties suitable for your super-resolution technique (photostability for STED, photoswitching for STORM/PALM)

  • Consider density of labeling (higher for structural studies, lower for counting applications)

• Technique-Specific Considerations:

  • STORM/PALM: Ensure appropriate blinking behavior of conjugated fluorophores

  • STED: Select fluorophores with good depletion efficiency

  • SIM: Optimize signal-to-noise ratio and sample preparation

  • Expansion Microscopy: Verify epitope preservation during expansion

• Sample Preparation Optimization:

  • Test different fixation protocols (may affect epitope accessibility)

  • Optimize permeabilization to balance antibody access with structural preservation

  • Use smaller probes (Fab fragments, nanobodies) for improved penetration and resolution

  • Consider tissue clearing techniques for thick specimens

• Validation Approaches:

  • Compare conventional and super-resolution imaging patterns

  • Perform correlative imaging with other techniques

  • Use known structural features as internal calibration

  • For nuclear proteins like PARP-1, compare with DNA staining patterns

• Quantitative Controls:

  • Measure labeling efficiency and specificity

  • Include fiducial markers for drift correction

  • Perform replicate experiments to assess reproducibility

  • Use simulation-based approaches to estimate resolution and precision

• Advanced Implementations:

  • Multiplexed imaging with complementary antibodies

  • Live-cell super-resolution (for suitable applications)

  • Correlative light and electron microscopy (CLEM)

  • Integration with expansion microscopy for further resolution enhancement

What are the current limitations of A6 antibodies in research applications?

Despite their utility, A6 antibodies face several methodological limitations in research applications:

• Epitope-Specific Constraints:

  • Some A6 antibodies recognize epitopes sensitive to sample preparation

  • The A6 antibody recognizing LCA has a carbohydrate-dependent epitope that is neuraminidase-sensitive

  • Certain fixation methods may mask or alter epitopes

  • The PARP-1 antibody A6.4.12 requires specific antigen retrieval for paraffin sections

• Cross-Reactivity Considerations:

  • Potential cross-reactivity with structurally similar proteins

  • The mAb 24-A6 epitope shows 83-100% similarity among deltacoronaviruses, suggesting potential cross-reactivity

  • Batch-to-batch variability may affect specificity profiles

  • Limited validation across diverse species or cellular contexts

• Technical Challenges:

  • Optimization required for each application (WB, IF, IHC, etc.)

  • Variable performance in multiplexed applications

  • Limited quantitative accuracy for some applications

  • Need for careful control experiments to validate results

• Application Gaps:

  • Limited validation for emerging techniques

  • Potential interference with protein function in live-cell applications

  • Suboptimal performance in certain buffer conditions or pH ranges

  • Challenges in detecting native protein conformations

• Production and Standardization Issues:

  • Potential for batch variation in hybridoma-derived antibodies

  • Limited standardization across research studies

  • Incomplete characterization of binding kinetics and affinities

  • Restricted availability of well-characterized derivatives (Fab fragments, etc.)

What future directions and emerging technologies might enhance A6 antibody applications?

Several promising methodological developments may expand the utility of A6 antibodies:

• Enhanced Engineering Approaches:

  • Recombinant antibody production for improved consistency

  • Affinity maturation to increase binding strength and specificity

  • Humanization for therapeutic applications

  • Format diversification (bispecific antibodies, nanobodies, etc.)

• Advanced Conjugation Technologies:

  • Site-specific conjugation to preserve binding properties

  • Novel reporter systems (quantum dots, DNA barcodes, etc.)

  • Stimuli-responsive fluorophores for dynamic applications

  • Proximity-based enzymatic tags for signal amplification

• Integration with Emerging Platforms:

  • Spatial multi-omics technologies combining antibody detection with DNA/RNA analysis

  • Microfluidic systems for automated, high-throughput analyses

  • Organ-on-chip models for functional antibody studies

  • AI-assisted image analysis for complex staining patterns

• Expanded Validation Resources:

  • Comprehensive cross-reactivity profiling across tissues and species

  • Standardized reporting of validation metrics

  • Open-access databases of antibody performance characteristics

  • Community-based validation initiatives

• Novel Application Areas:

  • Super-resolution expansion microscopy combining antibody detection with physical expansion

  • In vivo imaging with near-infrared or MRI-compatible conjugates

  • Targeted protein degradation applications

  • Theranostic applications combining detection and therapeutic functions

• Computational Integration:

  • Machine learning algorithms for pattern recognition in complex datasets

  • Predictive modeling of antibody-epitope interactions

  • Systems biology integration of antibody-generated data

  • Digital pathology workflows for automated analysis